RIGEL PHARMACEUTICALS INCRIGLEarnings & Financial Report
Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.
Revenue
$36.8M
Gross Profit
$34.0M
Operating Profit
$447.0K
Net Profit
$-1.0M
Gross Margin
92.4%
Operating Margin
1.2%
Net Margin
-2.8%
YoY Growth
37.0%
EPS
$-0.06
RIGEL PHARMACEUTICALS INC Q2 FY2024 Financial Summary
RIGEL PHARMACEUTICALS INC reported revenue of $36.8M (up 37.0% YoY) for Q2 FY2024, with a net profit of $-1.0M (up 84.4% YoY) (-2.8% margin). Cost of goods sold was $2.8M, operating expenses totaled $33.6M.
Key Financial Metrics
| Total Revenue | $36.8M |
|---|---|
| Net Profit | $-1.0M |
| Gross Margin | 92.4% |
| Operating Margin | 1.2% |
| Report Period | Q2 FY2024 |
Revenue Breakdown
RIGEL PHARMACEUTICALS INC Q2 FY2024 revenue of $36.8M breaks down across 3 segments, led by Products at $33.5M (90.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Products | $33.5M | 90.8% |
| Fostamatinib | $2.2M | 6.0% |
| Royalty | $1.1M | 3.0% |
RIGEL PHARMACEUTICALS INC Revenue by Segment — Quarterly Trend
RIGEL PHARMACEUTICALS INC revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and Fostamatinib) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Products | — | $64.1M | $58.9M | $43.5M |
| Fostamatinib | — | — | — | $1.6M |
| Royalty | — | $1.9M | — | $1.4M |
RIGEL PHARMACEUTICALS INC Annual Revenue by Year
RIGEL PHARMACEUTICALS INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $294.3M).
| Year | Annual Revenue |
|---|---|
| 2025 | $294.3M |
| 2024 | $179.3M |
| 2023 | $116.9M |
| 2022 | $120.2M |
RIGEL PHARMACEUTICALS INC Quarterly Revenue & Net Profit History
RIGEL PHARMACEUTICALS INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $69.8M | +21.2% | $268.1M | 384.0% |
| Q3 FY2025 | $69.5M | +25.6% | $27.9M | 40.2% |
| Q2 FY2025 | $101.7M | +176.0% | $59.6M | 58.6% |
| Q1 FY2025 | $53.3M | +80.6% | $11.4M | 21.5% |
| Q4 FY2024 | $57.6M | +60.9% | $14.3M | 24.9% |
| Q3 FY2024 | $55.3M | +96.6% | $12.4M | 22.5% |
| Q2 FY2024 | $36.8M | +37.0% | $-1.0M | -2.8% |
| Q1 FY2024 | $29.5M | +13.3% | $-8.2M | -27.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $29.5M | $36.8M | $55.3M | $57.6M | $53.3M | $101.7M | $69.5M | $69.8M |
| YoY Growth | 13.3% | 37.0% | 96.6% | 60.9% | 80.6% | 176.0% | 25.6% | 21.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $126.5M | $128.4M | $139.4M | $164.0M | $176.0M | $206.7M | $242.5M | $513.6M |
| Liabilities | $158.2M | $158.3M | $154.1M | $160.7M | $157.4M | $124.8M | $124.9M | $122.1M |
| Equity | $-31.7M | $-29.9M | $-14.6M | $3.3M | $18.6M | $81.9M | $117.6M | $391.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.0M | $302000 | $21.7M | $14.5M | $-893000 | $30.5M | $24.0M | $22.0M |